{
    "info": {
        "nct_id": "NCT06719362",
        "official_title": "A First-in-human, Open-label, Dose Escalation, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies in Patients With Advanced Solid Tumors",
        "inclusion_criteria": "1. Age ≥ 18 years.\n2. Life expectancy ≥ 12 weeks.\n3. Provision of written informed consent (see Section 16.1 and Appendix 18.5.5) for participation in the clinical trial.\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1 for subjects with solid tumors other than glioblastoma.\n5. Karnofsky Performance Status of ≥ 70% for subjects with glioblastoma.\n6. Tumor tissue from a surgical or core needle biopsy must be provided to the sponsor (fine needle aspirate or cytology specimens are not acceptable). Archival formalin fixed paraffin embedded (FFPE) tissue is acceptable. If archival tumor tissue is not available, a fresh tumor biopsy must be performed.\n7. Subjects must have a tumor accessible for biopsy while on treatment. If the subject does not have a tumor that is safely accessible for biopsy, the subject may still participate in the clinical trial following authorization from the sponsor. NOTE: Subjects with glioblastoma are not required to have tumor accessible for biopsy and will not undergo a protocol specified biopsy on study.\n8. Eligible tumor types in Part 1 Dose Escalation will include subjects with histologically or cytologically confirmed metastatic or unresectable solid tumors who have developed disease progression following standard systemic therapy in the unresectable or metastatic setting. Subjects with cancers that harbor a molecularly defined oncogenic target for which an FDA approved therapy is available (including but not limited to EGFR, ROS1, ALK, BRAF, RET, NTRK, KRAS G12C, etc.) should have received this therapy.\n9. Measurable disease\n\n   * Subjects with solid tumors other than glioblastoma must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n   * Subjects with glioblastoma: Part 1: must have measurable disease per Response Assessment in Neuro-Oncology (RANO 2.0); Part 2: measurable disease at baseline is not required as these subjects will have undergone maximal safe resection prior to enrollment.\n10. Adequate organ function as defined by the following:\n\n    * Absolute neutrophil count (ANC) ≥ 1.2 x 109/L.\n    * Hemoglobin ≥ 9.0 g/dL (without a blood transfusion 2 weeks prior to the hemoglobin measurement).\n    * Platelet count ≥ 100 x 109/L (without a platelet transfusion 2 weeks prior to the platelet measurement).\n    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.\n    * Total bilirubin ≤ 1.5 x ULN (or ≤ 3 x ULN for subjects with Gilbert's syndrome).\n    * International normalized ratio (INR) ≤ 1.5 x ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (unless the subject is being treated with anticoagulant medication).\n    * Serum albumin ≥ 2.8 g/dL.\n    * Creatinine clearance (measured or calculated) ≥ 30 mL/min.\n11. Female subjects of reproductive potential who are sexually active with a male partner must:\n\n    * Have a negative serum beta-human chorionic gonadotropin (β-HCG) test within 3 days of cycle 1 day 1.\n    * Agree to use highly effective contraceptive measures (as defined in protocol) from the time of enrollment through 3 months after the last dose of study drug in the clinical trial.\n    * Female subjects are considered to be of non-reproductive potential if they: have been amenorrheic for greater than 1 year or have undergone surgical sterilization through tubal ligation, oophorectomy or hysterectomy.\n12. Male subjects with a female partner of reproductive potential must agree to use highly effective contraception (as defined in protocol) from the time of enrollment through 3 months after the last dose of study drug administration.\n13. Subjects must agree to not donate sperm or eggs (ova, oocytes) for the purpose of reproduction from the time of enrollment through 3 months after the last dose of study drug administration.\n14. Toxicities from prior anti-cancer therapy must have resolved to grade ≤ 1.\n\n    * Exceptions include vitiligo, endocrinopathies managed with hormone replacement therapy, alopecia, and grade 2 neuropathy or hearing loss.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Treatment with anticancer therapy within 14 days or 5 half-lives (whichever is shorter) of cycle 1 day 1. Palliative radiation therapy to a non-CNS metastasis is permitted if completed at least 14 days prior to cycle 1 day 1.\n2. History of other active malignancy that required treatment within 2 years of enrollment. Exceptions include the following:\n\n   * Early-stage/localized tumors that have received definitive/curative treatment and have low risk of recurrence (including but not limited to cutaneous squamous cell or basal cell carcinoma, in situ cervical or bladder cancer, and early-stage prostate cancer).\n   * Early-stage prostate cancer in which observation without treatment is recommended.\n3. Clinically significant cardiovascular conditions as defined by the following:\n\n   * New York Heart Association (NYHA) congestive heart failure class ≥ II.\n   * Left ventricular ejection fraction ≤ 50%.\n   * Clinically significant cardiac arrhythmia requiring treatment within 3 months of enrollment. Subjects with cardiac arrhythmias on stable management for over 3 months prior to enrollment are permitted.\n   * Prolonged QTcF interval > 480 ms.\n   * Myocardial infarction, stroke, or pulmonary embolism within 3 months of enrollment.\n4. CNS metastases or leptomeningeal carcinomatosis (applicable to subjects with solid tumors other than glioblastoma). Subjects with brain metastases are eligible for participation if one of the following criteria are met:\n\n   * CNS metastases have been treated with surgical resection or radiation therapy and have remained stable for at least 4 weeks (repeat imaging required at least 4 weeks following resection or last radiation therapy) prior to cycle 1 day 1.\n   * The subject is neurologically asymptomatic and there are ≤ 4 CNS metastases no larger than 1 cm.\n5. Treatment with immunosuppressive medications.\n\n   - Treatment with corticosteroids greater than the equivalent of prednisone 10 mg/day within 2 weeks of cycle 1 day 1 is exclusionary. Exceptions include: Premedication with corticosteroids for iodine contrasted CT scans; Chronic use of ≤ 10 mg/day of prednisone (or equivalent). Topical, inhaled, and intra-articular corticosteroid use is allowed; Subjects with glioblastoma are permitted to be on ≤ 3 mg/day dexamethasone (or equivalent).\n6. History of severe pulmonary disease defined as either of the following:\n\n   * History of interstitial lung disease, non-infectious pneumonitis (including immune checkpoint inhibitor induced pneumonitis), or pulmonary fibrosis.\n   * Currently dependent on supplemental oxygen.\n7. History of allogeneic stem cell or solid organ transplantation.\n8. History of autoimmune disease that required systemic immunosuppressive therapy within 2 years of enrollment. Subjects with autoimmune diseases managed with hormone replacement or topical therapies are eligible.\n9. History of an immune-mediated adverse event from treatment with an immune checkpoint inhibitor that resulted in treatment discontinuation.\n\n   - Subjects who discontinued treatment with ipilimumab due to toxicity and subsequently tolerated treatment with an anti-PD-(L)1 inhibitor without treatment-limiting toxicity are eligible.\n10. History of severe hypersensitivity reaction (≥ grade 3) to infusion of a therapeutic monoclonal antibody.\n11. Any major surgery within 4 weeks of receiving the first dose of the investigational treatment.\n12. Women who are pregnant or breast feeding.\n13. Subjects with active (acute or chronic) bacterial, viral, or fungal infection at the time of enrollment are ineligible with the following exceptions:\n\n    * Subjects with human immunodeficiency virus (HIV) are eligible for participation if the following criteria are met: CD4+ T cell count ≥350 cells/µL, No history of AIDS-defining opportunistic infections within 12 months of enrollment, Subjects must be on antiretroviral therapy for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrollment.\n    * Subjects with chronic hepatitis B (HBV) who are on suppressive antiviral therapy prior to enrollment are eligible. Subjects with chronic HBV who are not eligible for treatment with suppressive antiviral therapy are ineligible.\n    * Subjects with a history of hepatitis C (HCV) infection who have completed curative antiviral treatment and have an HCV viral load below the limit of quantification are eligible.\n14. Ongoing drug or alcohol abuse at the time of enrollment.\n15. Any medical or psychiatric illness or social circumstance that could jeopardize compliance with the protocol directed treatment and safety assessments.\n\nAdditional Exclusion Criteria Specific for the Part 2A - Newly Diagnosed MGMT Unmethylated Glioblastoma Cohort:\n\n1. Subjects with recurrent or secondary GBM.\n2. Subjects who underwent biopsy only without maximal safe resection.\n3. Subjects with a contraindication to MRI scans.\n4. Subjects with IDH-1 or IDH-2 mutations or H3 K27M diffuse midline glioma.\n5. Subjects with unresolved CNS hemorrhage, leptomeningeal or spinal metastases or ventricular invasion.\n6. Subjects treated with a carmustine wafer implant.\n7. Subjects treated with Tumor Treating Fields (TTF).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Subjects with solid tumors other than glioblastoma must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with solid tumors other than glioblastoma",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "glioblastoma"
                        },
                        {
                            "requirement_type": "inclusion",
                            "expected_value": "solid tumors"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                    "criterion": "measurable disease (per RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Life expectancy ≥ 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 12 weeks.",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Provision of written informed consent (see Section 16.1 and Appendix 18.5.5) for participation in the clinical trial.",
            "criterions": [
                {
                    "exact_snippets": "Provision of written informed consent ... for participation in the clinical trial.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age ≥ 18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Karnofsky Performance Status of ≥ 70% for subjects with glioblastoma.",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky Performance Status of ≥ 70% for subjects with glioblastoma",
                    "criterion": "Karnofsky Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Subjects must have a tumor accessible for biopsy while on treatment. If the subject does not have a tumor that is safely accessible for biopsy, the subject may still participate in the clinical trial following authorization from the sponsor. NOTE: Subjects with glioblastoma are not required to have tumor accessible for biopsy and will not undergo a protocol specified biopsy on study.",
            "criterions": [
                {
                    "exact_snippets": "Subjects must have a tumor accessible for biopsy while on treatment.",
                    "criterion": "tumor accessibility for biopsy",
                    "requirements": [
                        {
                            "requirement_type": "accessibility for biopsy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If the subject does not have a tumor that is safely accessible for biopsy, the subject may still participate in the clinical trial following authorization from the sponsor.",
                    "criterion": "authorization from sponsor",
                    "requirements": [
                        {
                            "requirement_type": "authorization",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with glioblastoma are not required to have tumor accessible for biopsy and will not undergo a protocol specified biopsy on study.",
                    "criterion": "glioblastoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "requirement for tumor accessibility for biopsy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Tumor tissue from a surgical or core needle biopsy must be provided to the sponsor (fine needle aspirate or cytology specimens are not acceptable). Archival formalin fixed paraffin embedded (FFPE) tissue is acceptable. If archival tumor tissue is not available, a fresh tumor biopsy must be performed.",
            "criterions": [
                {
                    "exact_snippets": "Tumor tissue from a surgical or core needle biopsy must be provided to the sponsor (fine needle aspirate or cytology specimens are not acceptable)",
                    "criterion": "tumor tissue sample type",
                    "requirements": [
                        {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "surgical biopsy",
                                "core needle biopsy"
                            ]
                        },
                        {
                            "requirement_type": "exclusion sample type",
                            "expected_value": [
                                "fine needle aspirate",
                                "cytology specimens"
                            ]
                        },
                        {
                            "requirement_type": "provision to sponsor",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Archival formalin fixed paraffin embedded (FFPE) tissue is acceptable",
                    "criterion": "archival FFPE tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If archival tumor tissue is not available, a fresh tumor biopsy must be performed",
                    "criterion": "fresh tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "requirement if archival not available",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1 for subjects with solid tumors other than glioblastoma.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-1 for subjects with solid tumors other than glioblastoma.",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "applicable_condition",
                            "expected_value": "subjects with solid tumors other than glioblastoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Measurable disease",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Eligible tumor types in Part 1 Dose Escalation will include subjects with histologically or cytologically confirmed metastatic or unresectable solid tumors who have developed disease progression following standard systemic therapy in the unresectable or metastatic setting. Subjects with cancers that harbor a molecularly defined oncogenic target for which an FDA approved therapy is available (including but not limited to EGFR, ROS1, ALK, BRAF, RET, NTRK, KRAS G12C, etc.) should have received this therapy.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed metastatic or unresectable solid tumors",
                    "criterion": "solid tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "metastatic",
                                "unresectable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have developed disease progression following standard systemic therapy in the unresectable or metastatic setting",
                    "criterion": "disease progression after standard systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "disease progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior therapy",
                            "expected_value": "standard systemic therapy in the unresectable or metastatic setting"
                        }
                    ]
                },
                {
                    "exact_snippets": "cancers that harbor a molecularly defined oncogenic target for which an FDA approved therapy is available (including but not limited to EGFR, ROS1, ALK, BRAF, RET, NTRK, KRAS G12C, etc.) should have received this therapy",
                    "criterion": "molecularly defined oncogenic target with available FDA approved therapy",
                    "requirements": [
                        {
                            "requirement_type": "oncogenic target",
                            "expected_value": "molecularly defined"
                        },
                        {
                            "requirement_type": "FDA approved therapy available",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior therapy",
                            "expected_value": "should have received this therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Adequate organ function as defined by the following:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with glioblastoma: Part 1: must have measurable disease per Response Assessment in Neuro-Oncology (RANO 2.0); Part 2: measurable disease at baseline is not required as these subjects will have undergone maximal safe resection prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with glioblastoma",
                    "criterion": "glioblastoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Part 1: must have measurable disease per Response Assessment in Neuro-Oncology (RANO 2.0)",
                    "criterion": "measurable disease (per RANO 2.0)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Part 2: measurable disease at baseline is not required as these subjects will have undergone maximal safe resection prior to enrollment",
                    "criterion": "measurable disease at baseline (Part 2)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Part 2: ... these subjects will have undergone maximal safe resection prior to enrollment",
                    "criterion": "maximal safe resection prior to enrollment (Part 2)",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 9.0 g/dL (without a blood transfusion 2 weeks prior to the hemoglobin measurement).",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without a blood transfusion 2 weeks prior to the hemoglobin measurement",
                    "criterion": "blood transfusion within 2 weeks prior to hemoglobin measurement",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN.",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... ≤ 3 x ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ≤ 3 x ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤ 1.5 x ULN (or ≤ 3 x ULN for subjects with Gilbert's syndrome).",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≤ 3 x ULN for subjects with Gilbert's syndrome",
                    "criterion": "total bilirubin in subjects with Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "Gilbert's syndrome"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin ≥ 2.8 g/dL.",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin ≥ 2.8 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Female subjects of reproductive potential who are sexually active with a male partner must:",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of reproductive potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active with a male partner",
                    "criterion": "sexual activity with male partner",
                    "requirements": [
                        {
                            "requirement_type": "sexual activity with male partner",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance (measured or calculated) ≥ 30 mL/min.",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance (measured or calculated) ≥ 30 mL/min.",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) ≤ 1.5 x ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (unless the subject is being treated with anticoagulant medication).",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ≤ 1.5 x ULN",
                    "criterion": "International normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the subject is being treated with anticoagulant medication",
                    "criterion": "anticoagulant medication treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a negative serum beta-human chorionic gonadotropin (β-HCG) test within 3 days of cycle 1 day 1.",
            "criterions": [
                {
                    "exact_snippets": "negative serum beta-human chorionic gonadotropin (β-HCG) test within 3 days of cycle 1 day 1",
                    "criterion": "serum beta-human chorionic gonadotropin (β-HCG) test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 3 days of cycle 1 day 1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Subjects must agree to not donate sperm or eggs (ova, oocytes) for the purpose of reproduction from the time of enrollment through 3 months after the last dose of study drug administration.",
            "criterions": [
                {
                    "exact_snippets": "Subjects must agree to not donate sperm or eggs (ova, oocytes) for the purpose of reproduction from the time of enrollment through 3 months after the last dose of study drug administration.",
                    "criterion": "donation of sperm or eggs for reproduction",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "from the time of enrollment through 3 months after the last dose of study drug administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Toxicities from prior anti-cancer therapy must have resolved to grade ≤ 1.",
            "criterions": [
                {
                    "exact_snippets": "Toxicities from prior anti-cancer therapy must have resolved to grade ≤ 1.",
                    "criterion": "toxicities from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects are considered to be of non-reproductive potential if they: have been amenorrheic for greater than 1 year or have undergone surgical sterilization through tubal ligation, oophorectomy or hysterectomy.",
            "criterions": [
                {
                    "exact_snippets": "have been amenorrheic for greater than 1 year",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have undergone surgical sterilization through tubal ligation",
                    "criterion": "surgical sterilization (tubal ligation)",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have undergone surgical sterilization through ... oophorectomy",
                    "criterion": "surgical sterilization (oophorectomy)",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have undergone surgical sterilization through ... hysterectomy",
                    "criterion": "surgical sterilization (hysterectomy)",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions include vitiligo, endocrinopathies managed with hormone replacement therapy, alopecia, and grade 2 neuropathy or hearing loss.",
            "criterions": [
                {
                    "exact_snippets": "vitiligo",
                    "criterion": "vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "endocrinopathies managed with hormone replacement therapy",
                    "criterion": "endocrinopathies",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "hormone replacement therapy"
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 2 neuropathy or hearing loss",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 2 neuropathy or hearing loss",
                    "criterion": "hearing loss",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agree to use highly effective contraceptive measures (as defined in protocol) from the time of enrollment through 3 months after the last dose of study drug in the clinical trial.",
            "criterions": [
                {
                    "exact_snippets": "Agree to use highly effective contraceptive measures (as defined in protocol) from the time of enrollment through 3 months after the last dose of study drug in the clinical trial.",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "highly effective contraceptive measures"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from the time of enrollment through 3 months after the last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Male subjects with a female partner of reproductive potential must agree to use highly effective contraception (as defined in protocol) from the time of enrollment through 3 months after the last dose of study drug administration.",
            "criterions": [
                {
                    "exact_snippets": "Male subjects with a female partner of reproductive potential",
                    "criterion": "male subject with a female partner of reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use highly effective contraception (as defined in protocol) from the time of enrollment through 3 months after the last dose of study drug administration",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": "highly effective contraception"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from the time of enrollment through 3 months after the last dose of study drug administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Left ventricular ejection fraction ≤ 50%.",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction ≤ 50%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of interstitial lung disease, non-infectious pneumonitis (including immune checkpoint inhibitor induced pneumonitis), or pulmonary fibrosis.",
            "criterions": [
                {
                    "exact_snippets": "History of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... non-infectious pneumonitis (including immune checkpoint inhibitor induced pneumonitis)",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... pulmonary fibrosis",
                    "criterion": "pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Women who are pregnant or breast feeding.",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast feeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with a history of hepatitis C (HCV) infection who have completed curative antiviral treatment and have an HCV viral load below the limit of quantification are eligible.",
            "criterions": [
                {
                    "exact_snippets": "history of hepatitis C (HCV) infection",
                    "criterion": "hepatitis C (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have completed curative antiviral treatment",
                    "criterion": "curative antiviral treatment for HCV",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HCV viral load below the limit of quantification",
                    "criterion": "HCV viral load",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0,
                                "unit": "limit of quantification"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. History of severe pulmonary disease defined as either of the following:",
            "criterions": [
                {
                    "exact_snippets": "History of severe pulmonary disease",
                    "criterion": "severe pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Any major surgery within 4 weeks of receiving the first dose of the investigational treatment.",
            "criterions": [
                {
                    "exact_snippets": "Any major surgery within 4 weeks of receiving the first dose of the investigational treatment.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects with IDH-1 or IDH-2 mutations or H3 K27M diffuse midline glioma.",
            "criterions": [
                {
                    "exact_snippets": "IDH-1 or IDH-2 mutations",
                    "criterion": "IDH-1 mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "IDH-1 or IDH-2 mutations",
                    "criterion": "IDH-2 mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "H3 K27M diffuse midline glioma",
                    "criterion": "H3 K27M diffuse midline glioma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. History of severe hypersensitivity reaction (≥ grade 3) to infusion of a therapeutic monoclonal antibody.",
            "criterions": [
                {
                    "exact_snippets": "History of severe hypersensitivity reaction (≥ grade 3) to infusion of a therapeutic monoclonal antibody",
                    "criterion": "hypersensitivity reaction to infusion of a therapeutic monoclonal antibody",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject is neurologically asymptomatic and there are ≤ 4 CNS metastases no larger than 1 cm.",
            "criterions": [
                {
                    "exact_snippets": "neurologically asymptomatic",
                    "criterion": "neurological symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "≤ 4 CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "metastases"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no larger than 1 cm",
                    "criterion": "CNS metastasis size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Treatment with corticosteroids greater than the equivalent of prednisone 10 mg/day within 2 weeks of cycle 1 day 1 is exclusionary. Exceptions include: Premedication with corticosteroids for iodine contrasted CT scans; Chronic use of ≤ 10 mg/day of prednisone (or equivalent). Topical, inhaled, and intra-articular corticosteroid use is allowed; Subjects with glioblastoma are permitted to be on ≤ 3 mg/day dexamethasone (or equivalent).",
            "criterions": [
                {
                    "exact_snippets": "Treatment with corticosteroids greater than the equivalent of prednisone 10 mg/day within 2 weeks of cycle 1 day 1 is exclusionary.",
                    "criterion": "corticosteroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 2 weeks of cycle 1 day 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Premedication with corticosteroids for iodine contrasted CT scans",
                    "criterion": "corticosteroid premedication for iodine contrasted CT scans",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic use of ≤ 10 mg/day of prednisone (or equivalent)",
                    "criterion": "chronic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Topical, inhaled, and intra-articular corticosteroid use is allowed",
                    "criterion": "topical, inhaled, and intra-articular corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with glioblastoma are permitted to be on ≤ 3 mg/day dexamethasone (or equivalent)",
                    "criterion": "dexamethasone use in subjects with glioblastoma",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "mg/day dexamethasone equivalent"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "glioblastoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Subjects treated with a carmustine wafer implant.",
            "criterions": [
                {
                    "exact_snippets": "Subjects treated with a carmustine wafer implant",
                    "criterion": "carmustine wafer implant treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently dependent on supplemental oxygen.",
            "criterions": [
                {
                    "exact_snippets": "Currently dependent on supplemental oxygen",
                    "criterion": "supplemental oxygen dependence",
                    "requirements": [
                        {
                            "requirement_type": "current dependence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Early-stage prostate cancer in which observation without treatment is recommended.",
            "criterions": [
                {
                    "exact_snippets": "Early-stage prostate cancer",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "early-stage"
                        }
                    ]
                },
                {
                    "exact_snippets": "observation without treatment is recommended",
                    "criterion": "treatment recommendation",
                    "requirements": [
                        {
                            "requirement_type": "recommended management",
                            "expected_value": "observation without treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with human immunodeficiency virus (HIV) are eligible for participation if the following criteria are met: CD4+ T cell count ≥350 cells/µL, No history of AIDS-defining opportunistic infections within 12 months of enrollment, Subjects must be on antiretroviral therapy for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "CD4+ T cell count ≥350 cells/µL",
                    "criterion": "CD4+ T cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 350,
                                "unit": "cells/µL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "No history of AIDS-defining opportunistic infections within 12 months of enrollment",
                    "criterion": "AIDS-defining opportunistic infections",
                    "requirements": [
                        {
                            "requirement_type": "history within 12 months of enrollment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects must be on antiretroviral therapy for at least 4 weeks",
                    "criterion": "antiretroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV viral load less than 400 copies/mL prior to enrollment",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "quantity prior to enrollment",
                            "expected_value": {
                                "operator": "<",
                                "value": 400,
                                "unit": "copies/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Subjects with a contraindication to MRI scans.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with a contraindication to MRI scans",
                    "criterion": "contraindication to MRI scans",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Subjects who discontinued treatment with ipilimumab due to toxicity and subsequently tolerated treatment with an anti-PD-(L)1 inhibitor without treatment-limiting toxicity are eligible.",
            "criterions": [
                {
                    "exact_snippets": "discontinued treatment with ipilimumab due to toxicity",
                    "criterion": "ipilimumab treatment discontinuation due to toxicity",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_reason",
                            "expected_value": "toxicity"
                        }
                    ]
                },
                {
                    "exact_snippets": "subsequently tolerated treatment with an anti-PD-(L)1 inhibitor without treatment-limiting toxicity",
                    "criterion": "tolerance to anti-PD-(L)1 inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment-limiting toxicity",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Subjects with unresolved CNS hemorrhage, leptomeningeal or spinal metastases or ventricular invasion.",
            "criterions": [
                {
                    "exact_snippets": "unresolved CNS hemorrhage",
                    "criterion": "CNS hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal ... metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "spinal metastases",
                    "criterion": "spinal metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ventricular invasion",
                    "criterion": "ventricular invasion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Additional Exclusion Criteria Specific for the Part 2A - Newly Diagnosed MGMT Unmethylated Glioblastoma Cohort:",
            "criterions": [
                {
                    "exact_snippets": "Newly Diagnosed MGMT Unmethylated Glioblastoma Cohort",
                    "criterion": "glioblastoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        },
                        {
                            "requirement_type": "MGMT methylation status",
                            "expected_value": "unmethylated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Clinically significant cardiovascular conditions as defined by the following:",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular conditions",
                    "criterion": "cardiovascular conditions",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Subjects with recurrent or secondary GBM.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with recurrent or secondary GBM",
                    "criterion": "GBM (glioblastoma multiforme)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "recurrent",
                                "secondary"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prolonged QTcF interval > 480 ms.",
            "criterions": [
                {
                    "exact_snippets": "Prolonged QTcF interval > 480 ms.",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Subjects with active (acute or chronic) bacterial, viral, or fungal infection at the time of enrollment are ineligible with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Subjects with active (acute or chronic) bacterial, viral, or fungal infection at the time of enrollment are ineligible",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "infection_type",
                            "expected_value": [
                                "bacterial",
                                "viral",
                                "fungal"
                            ]
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with chronic hepatitis B (HBV) who are on suppressive antiviral therapy prior to enrollment are eligible. Subjects with chronic HBV who are not eligible for treatment with suppressive antiviral therapy are ineligible.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with chronic hepatitis B (HBV) who are on suppressive antiviral therapy prior to enrollment are eligible.",
                    "criterion": "chronic hepatitis B (HBV)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "who are on suppressive antiviral therapy prior to enrollment",
                    "criterion": "suppressive antiviral therapy for HBV",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with chronic HBV who are not eligible for treatment with suppressive antiviral therapy are ineligible.",
                    "criterion": "eligibility for suppressive antiviral therapy for HBV",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Subjects who underwent biopsy only without maximal safe resection.",
            "criterions": [
                {
                    "exact_snippets": "underwent biopsy only",
                    "criterion": "biopsy",
                    "requirements": [
                        {
                            "requirement_type": "procedure_type",
                            "expected_value": "biopsy only"
                        }
                    ]
                },
                {
                    "exact_snippets": "without maximal safe resection",
                    "criterion": "maximal safe resection",
                    "requirements": [
                        {
                            "requirement_type": "procedure_history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Treatment with immunosuppressive medications.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with immunosuppressive medications.",
                    "criterion": "immunosuppressive medication treatment",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. History of allogeneic stem cell or solid organ transplantation.",
            "criterions": [
                {
                    "exact_snippets": "History of allogeneic stem cell or solid organ transplantation.",
                    "criterion": "history of allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of allogeneic stem cell or solid organ transplantation.",
                    "criterion": "history of solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Early-stage/localized tumors that have received definitive/curative treatment and have low risk of recurrence (including but not limited to cutaneous squamous cell or basal cell carcinoma, in situ cervical or bladder cancer, and early-stage prostate cancer).",
            "criterions": [
                {
                    "exact_snippets": "Early-stage/localized tumors",
                    "criterion": "tumor stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "early-stage",
                                "localized"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have received definitive/curative treatment",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "definitive",
                                "curative"
                            ]
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "received"
                        }
                    ]
                },
                {
                    "exact_snippets": "have low risk of recurrence",
                    "criterion": "risk of recurrence",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "low"
                        }
                    ]
                },
                {
                    "exact_snippets": "including but not limited to cutaneous squamous cell or basal cell carcinoma, in situ cervical or bladder cancer, and early-stage prostate cancer",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "cutaneous squamous cell carcinoma",
                                "basal cell carcinoma",
                                "in situ cervical cancer",
                                "in situ bladder cancer",
                                "early-stage prostate cancer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Subjects treated with Tumor Treating Fields (TTF).",
            "criterions": [
                {
                    "exact_snippets": "Subjects treated with Tumor Treating Fields (TTF)",
                    "criterion": "Tumor Treating Fields (TTF) treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Any medical or psychiatric illness or social circumstance that could jeopardize compliance with the protocol directed treatment and safety assessments.",
            "criterions": [
                {
                    "exact_snippets": "Any medical or psychiatric illness ... that could jeopardize compliance with the protocol directed treatment and safety assessments.",
                    "criterion": "medical illness",
                    "requirements": [
                        {
                            "requirement_type": "potential to jeopardize compliance with protocol directed treatment and safety assessments",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any medical or psychiatric illness ... that could jeopardize compliance with the protocol directed treatment and safety assessments.",
                    "criterion": "psychiatric illness",
                    "requirements": [
                        {
                            "requirement_type": "potential to jeopardize compliance with protocol directed treatment and safety assessments",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... social circumstance that could jeopardize compliance with the protocol directed treatment and safety assessments.",
                    "criterion": "social circumstance",
                    "requirements": [
                        {
                            "requirement_type": "potential to jeopardize compliance with protocol directed treatment and safety assessments",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. History of an immune-mediated adverse event from treatment with an immune checkpoint inhibitor that resulted in treatment discontinuation.",
            "criterions": [
                {
                    "exact_snippets": "History of an immune-mediated adverse event from treatment with an immune checkpoint inhibitor that resulted in treatment discontinuation.",
                    "criterion": "immune-mediated adverse event from immune checkpoint inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause of event",
                            "expected_value": "immune checkpoint inhibitor"
                        },
                        {
                            "requirement_type": "outcome",
                            "expected_value": "treatment discontinuation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CNS metastases have been treated with surgical resection or radiation therapy and have remained stable for at least 4 weeks (repeat imaging required at least 4 weeks following resection or last radiation therapy) prior to cycle 1 day 1.",
            "criterions": [
                {
                    "exact_snippets": "CNS metastases have been treated with surgical resection or radiation therapy",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "surgical resection",
                                "radiation therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have remained stable for at least 4 weeks",
                    "criterion": "CNS metastases stability",
                    "requirements": [
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "repeat imaging required at least 4 weeks following resection or last radiation therapy",
                    "criterion": "repeat imaging after CNS metastases treatment",
                    "requirements": [
                        {
                            "requirement_type": "imaging_timing",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myocardial infarction, stroke, or pulmonary embolism within 3 months of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Myocardial infarction ... within 3 months of enrollment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke ... within 3 months of enrollment",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary embolism within 3 months of enrollment",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Treatment with anticancer therapy within 14 days or 5 half-lives (whichever is shorter) of cycle 1 day 1. Palliative radiation therapy to a non-CNS metastasis is permitted if completed at least 14 days prior to cycle 1 day 1.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with anticancer therapy within 14 days or 5 half-lives (whichever is shorter) of cycle 1 day 1",
                    "criterion": "anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment-free interval before cycle 1 day 1",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Palliative radiation therapy to a non-CNS metastasis is permitted if completed at least 14 days prior to cycle 1 day 1",
                    "criterion": "palliative radiation therapy to a non-CNS metastasis",
                    "requirements": [
                        {
                            "requirement_type": "completion before cycle 1 day 1",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiac arrhythmia requiring treatment within 3 months of enrollment. Subjects with cardiac arrhythmias on stable management for over 3 months prior to enrollment are permitted.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiac arrhythmia requiring treatment within 3 months of enrollment",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since treatment initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with cardiac arrhythmias on stable management for over 3 months prior to enrollment are permitted",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "stable management duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of autoimmune disease that required systemic immunosuppressive therapy within 2 years of enrollment. Subjects with autoimmune diseases managed with hormone replacement or topical therapies are eligible.",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune disease that required systemic immunosuppressive therapy within 2 years of enrollment",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic immunosuppressive therapy requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with autoimmune diseases managed with hormone replacement or topical therapies are eligible",
                    "criterion": "autoimmune disease management",
                    "requirements": [
                        {
                            "requirement_type": "management method",
                            "expected_value": [
                                "hormone replacement",
                                "topical therapies"
                            ]
                        },
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. History of other active malignancy that required treatment within 2 years of enrollment. Exceptions include the following:",
            "criterions": [
                {
                    "exact_snippets": "History of other active malignancy that required treatment within 2 years of enrollment",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_required_within_years_of_enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New York Heart Association (NYHA) congestive heart failure class ≥ II.",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association (NYHA) congestive heart failure class ≥ II",
                    "criterion": "NYHA congestive heart failure class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Ongoing drug or alcohol abuse at the time of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Ongoing drug or alcohol abuse at the time of enrollment",
                    "criterion": "drug abuse",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Ongoing drug or alcohol abuse at the time of enrollment",
                    "criterion": "alcohol abuse",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. CNS metastases or leptomeningeal carcinomatosis (applicable to subjects with solid tumors other than glioblastoma). Subjects with brain metastases are eligible for participation if one of the following criteria are met:",
            "criterions": [
                {
                    "exact_snippets": "CNS metastases or leptomeningeal carcinomatosis (applicable to subjects with solid tumors other than glioblastoma)",
                    "criterion": "CNS metastases or leptomeningeal carcinomatosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "tumor type",
                            "expected_value": "solid tumors other than glioblastoma"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with brain metastases are eligible for participation if one of the following criteria are met",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Platelet count ≥ 100 x 109/L (without a platelet transfusion 2 weeks prior to the platelet measurement).",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100 x 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without a platelet transfusion 2 weeks prior to the platelet measurement",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence within time window",
                            "expected_value": "no platelet transfusion within 2 weeks prior to measurement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 1.2 x 109/L.",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.2 x 10^9/L.",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.2,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}